ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.2240A>G (p.Glu747Gly) (rs397507283)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000215823 SCV000277257 uncertain significance Hereditary cancer-predisposing syndrome 2015-07-16 criteria provided, single submitter clinical testing
Color RCV000215823 SCV000903248 uncertain significance Hereditary cancer-predisposing syndrome 2018-06-01 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000487003 SCV000591796 uncertain significance not specified 2014-09-10 criteria provided, single submitter clinical testing
GeneDx RCV000657147 SCV000571741 uncertain significance not provided 2018-02-13 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.2240A>G at the cDNA level, p.Glu747Gly (E747G) at the protein level, and results in the change of a Glutamic Acid to a Glycine (GAA>GGA). Using alternate nomenclature, this variant would be defined as BRCA2 2468A>G. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 Glu747Gly was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is not located in a known functional domain. In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether BRCA2 Glu747Gly is pathogenic or benign. We consider it to be a variant of uncertain significance.
Integrated Genetics/Laboratory Corporation of America RCV000487003 SCV000918823 uncertain significance not specified 2017-11-06 criteria provided, single submitter clinical testing Variant summary: The BRCA2 c.2240A>G (p.Glu747Gly) variant involves the alteration of a non-conserved nucleotide. 3/5 in silico tools predict a damaging outcome for this variant, however these predictions have yet to be confirmed by functional studies. This variant was found in 9/246080 control chromosomes at a frequency of 0.0000366, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA2 variant (0.0007503). The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases; nor evaluated for functional impact by in vivo/vitro studies. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as uncertain significance. Because of the absence of clinical information and the lack of functional studies, the variant is classified as a variant of uncertain significance (VUS) until additional information becomes available.
Invitae RCV000204756 SCV000262417 uncertain significance Hereditary breast and ovarian cancer syndrome 2018-08-06 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid with glycine at codon 747 of the BRCA2 protein (p.Glu747Gly). The glutamic acid residue is weakly conserved and there is a moderate physicochemical difference between glutamic acid and glycine. This variant is present in population databases (rs397507283, ExAC 0.03%). This variant has been reported in an individual with breast cancer in the Leiden Open-source Variation Database (PMID: 21520333). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glycine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000487003 SCV000600505 uncertain significance not specified 2017-05-24 criteria provided, single submitter clinical testing
Sharing Clinical Reports Project (SCRP) RCV000031359 SCV000053964 uncertain significance Breast-ovarian cancer, familial 2 2010-07-30 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.